Benitec Biopharma
🇺🇸United States
A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia
Phase 1
Recruiting
- Conditions
- Oculopharyngeal Muscular Dystrophy
- First Posted Date
- 2023-12-29
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Benitec Biopharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06185673
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2
Completed
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Drug: BB-401
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Benitec Biopharma, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03433027
- Locations
- 🇦🇺
The Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺Calvary Central Districts Hospital, Elizabeth Vale, South Australia, Australia
🇷🇺Irkutsk Oncology Center, Irkutsk, Russian Federation
© Copyright 2025. All Rights Reserved by MedPath